Bank Of New York Mellon Corp Talaris Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.94 - $1.64 $55,045 - $96,036	58,559 New	58,559 $59,000
Q3 2022 Nov 14, 2022	BUY	$2.3 - $5.03 $16,357 - $35,773	7,112 Added 12.12%	65,806 $173,000
Q2 2022 Aug 15, 2022	SELL	$4.51 - $9.85 $4,185 - $9,140	-928 Reduced 1.56%	58,694 $265,000
Q1 2022 May 11, 2022	BUY	$6.89 - $16.56 $42,704 - $102,638	6,198 Added 11.6%	59,622 $586,000
Q4 2021 Feb 11, 2022	BUY	$12.18 - $17.0 $316,704 - $442,034	26,002 Added 94.82%	53,424 $817,000
Q3 2021 Nov 12, 2021	BUY	$11.61 - $15.99 $123,565 - $170,181	10,643 Added 63.43%	27,422 $372,000
Q2 2021 Aug 11, 2021	BUY	$12.25 - $18.61 $205,542 - $312,257	16,779 New	16,779 $246,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.